Noema Pharma has raised a $112M Series B funding round to create therapies for central nervous system disorders such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Childhood Onset Fluency Disorder.
The company is based in Switzerland.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system disorders characterized by imbalanced neuronal networks.
- Sofinnova Partners, Polaris Partners, Gilde Healthcare, Invus, Forbion, Jeito Capital, and UPMC Enterprises provided the funding.
- This funding will be used to boost the company's clinical-stage progress in creating therapies for conditions such as:
- Tourette Syndrome,
- Tuberous Sclerosis Complex,
- Childhood Onset Fluency Disorder,
- Trigeminal Neuralgia, etc.
- Since its inception in 2019, the company has raised around $175M.
- The company is based in Basel, Switzerland.
